Abstract
α-Difluoromethylornithine (DFMO) is a known irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis. Cyclosporine (CsA) has been reported to inhibit ODC activity in vitro. In the present study, we compared the effects of DFMO and CsA on growth, survival, and polyamine levels in mouse colon cancer (MC-26) and hamster pancreatic cancer (H2T) cells in vitro. The growth and survival of MC-26 and H2T cells were inhibited by both DFMO and CsA. However, H2T cells were observed to be significantly more sensitive than MC-26 cells to both CsA and DFMO. The inhibitory effects of CsA were blocked by the addition of the polyamine, putrescine, in both MC-26 and H2T cells. Polyamine levels were altered significantly in both MC-26 and H2T cells treated with CsA and DFMO. However, the profile of these alterations differed between MC-26 and H2T cell lines. Putrescine and spermidine levels in MC-26 cells were more sensitive to DFMO inhibition than were H2T cells. Spermine levels were consistently elevated in MC-26 cells exposed to CsA or DFMO, while the level of spermine in H2T cells decreased significantly in response to the same drugs. These results suggest that CsA and DFMO exhibit different effects on colon and pancreatic cancer growth in vitro. In addition, the differences in the sensitivity of pancreatic and colon cancer to CsA and DFMO indicate potentially important differences in polyamine metabolism between the two cell lines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tabor CW, Tabor H: Polyamines. Ann Rev Biochem 53:749–790, 1984
Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol 243:C212-C221, 1982
Pegg AE: Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 234:249–262, 1986
Porter CW, Sufrin JR: Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. Anticancer Res 6:525–542, 1986
Mamont PS, Duchesne M-C, Grove J, Bey P: Anti-proliferative properties of DL-α-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81:58–66, 1978
Saydjari R, Townsend Jr CM, Barranco SC, James E, Thompson JC: Effects of cyclosporin A and α-difluoro-methylornithine on the growth of hamster pancreatic cancer in vitro. JNCI 77:1087–1092, 1986
Saydjari R, Townsend Jr CM, Barranco SC, Thompson JC: Effects of cyclospirine A and α-difluoromethylornithine on the growth of mouse colon cancer in vitro. Life Sci 40:359–366, 1987
Prakash NJ, Schechter PJ, Grove J, Koch-Weser J: Effect of α-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice. Cancer Res 38:3059–3062, 1978
Koch-Weser J, Schechter PJ, Bey P, Danzin C, Fozard JR, Jung MJ, Mamont PS, Seiler N: Potential of ornithine decarboxylase inhibitor as therapeutic agents. In: Morris DR and Marton LJ (ed) Polyamines in Biology and Medicine. Marcel Dekker Inc, New York, 1981, pp 437–453
Kingsnorth AN, Russell WE, McCann PP, Diekema KA, Malt RA: Effects of α-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line. Cancer Res 43:4035–4038, 1983
Thomson AW: Immunobiology of cyclosporin A — a review. Aust J Exp Biol Med Sci 61 (Pt. 2):147–172, 1983
Fidelus RK, Laugher AH, Twomey JJ, Taffet SM, Haddos MK: The effect of cyclosporin on ornithine decarboxylase induction with mitogens, antigens, and lymphokines. Transplatation 37:383–386, 1984
Corbett TH, Griswold DP, Roberts BJ, Peckham J, Schabel Jr FM: A mouse colon-tumor model for experimental therapy. Cancer Chemother Rep 5 (Part 2): 169–186, 1975
Townsend Jr CM, Franklin RB, Gelder FB, Glass E, Thompson JC: Development of a transplantable model of pancreatic duct adenocarcinoma. Surgery 92:72–78, 1982
Saydjari R, Glass EJ, Townsend Jr CM, Gifford RRM, Thompson JC: Effects of cyclosporin A and α-difluoromethylornithine on the growth of pancreatic cancer in vitro. (Abstr) Dig Dis Sci 29:968, 1984
Morton JM, Poulter CA, Pandya KJ: Alimentary tract cancer. In: Rubin P (ed) Clinical Oncology. American Cancer Society, Rochester, 1983, pp 154–176
Alarcon J, Greenwood GR: Adenocarcinoma of the colon and rectum: A review of surgical treatment in 302 patients. Dis Col Rect 22:35–39, 1979
Malt RA: Treatment of pancreatic cancer. JAMA 250: 1433–1437, 1983
Merker MM, Handschumacher RE: Uptake and nature of the intracellular binding of cyclosporin A in murine thymoma cell line, BW5147. J Immunol 132:3064–3070, 1984
Handschumacher RE, Harding MW, Rice J, Drugge RJ: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 26:544–546, 1984
Kronke M, Leonard WJ, Depper JM, Arya SK, Wong-Staal F, Gallo RC, Waldmann TA, Greene WC: Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Nad Acad Sci USA 81: 5214–5218, 1984
Russell DH, Larson DF, Cardon SB, Copeland JG: Cyclosporin inhibits prolactin induction of ornithine decarboxylase in rat tissues. Molec Cell Endocrinol 35:159–166, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saydjari, R., Townsend, C.M., Barranco, S.C. et al. Cyclosporine and α-difluoromethylornithine exhibit differential effects on colon and pancreatic cancer in vitro . Invest New Drugs 5, 251–258 (1987). https://doi.org/10.1007/BF00175295
Issue Date:
DOI: https://doi.org/10.1007/BF00175295